Side-by-side comparison of AI visibility scores, market position, and capabilities
Smart ring maker raised $900M at $11B valuation in Oct 2025; projects $1B+ revenue in 2025 and $1.5B in 2026.
Oura is a Finnish health technology company best known for its smart ring — a wearable that tracks sleep, heart rate variability, body temperature, and readiness scores. Founded in 2013 and headquartered in San Francisco with R&D roots in Oulu, Finland, the company has shipped over 5.5 million rings globally since 2015, with nearly 3 million sold in 2025 alone.\n\nIn October 2025, Oura closed a $900M Series E led by Fidelity Management & Research, with participation from Iconiq, Whale Rock, and Atreides, pushing its valuation to approximately $11 billion — more than double its prior $5.2B round. The company reported over $500 million in revenue in 2024 and projected sales to exceed $1 billion in 2025, with a $1.5 billion forecast for 2026. Revenue is roughly 80% hardware and 20% monthly subscriptions at $6 per member.\n\nOura has built a strong enterprise and healthcare channel, partnering with the NBA, NFL, and major health systems to position the ring as a clinical-grade passive monitoring device. The subscription layer, with 2 million paying members, underpins a high-retention, recurring-revenue model that differentiates it from commoditized fitness trackers.
Raised $900M Series E at $11B valuation (Oct 2025). CEO projects ~$2B in 2026 sales. Launched women's health LLM (Feb 2026). Team USA LA28 Olympic partner.
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E financing at an $11 billion valuation in October 2025, reflecting the doubling of its revenue to $500 million in 2024 and a projected $1.5–2 billion in 2026 sales as it expands global distribution into India, UAE, and Latin America.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.